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Autologous Peripheral Stem Cell Transplantation for Patients With Relapsed 
Hodgkin’s Disease 
By  Anne Kessinger, Philip J. Bierman, Julie M. Vose, and James 0.  Armitage 
Between February 1986 and March 1990,  56 patients with 
relapsed Hodgkin‘s disease  treated with high-dose  cyclophos- 
phamide, carmustine, and etoposide (CBV) received an autol- 
ogous  peripheral  stem  cell  transplantation  (PSCT)  rather 
than  an  autologous  bone marrow transplantation  (ABMT) 
because each  patient  had  a  marrow  abnormality,  either 
hypocellularity  or  tumor  involvement.  At  least  6.5  x  10’ 
mononuclear cells/kg patient weight were collected from the 
peripheral  blood  of  each  patient,  cyropreserved,  and  re- 
turned intravenously following CBV  administration.  Three 
patients had an early death 2,22, and 25 days after PSCT. The 
actuarial event-free survival for these 56 patients at 3 years 
UTOLOGOUS PERIPHERAL stem cell transplanta-  A  tion (PSCT) has been used in a manner analogous to 
autologous  bone marrow transplantation  (ABMT)  as  a 
method to  restore marrow function following the adminis- 
tration of  marrow-ablative high-dose  therapy intended to 
eradicate certain ma1ignan~ies.I.~  The two indications for 
the use of PSCT rather than ABMT have been either the 
presence of a marrow abnormality, such as hypocellularity 
or  malignant  involvement,  that  precluded  the  use  of 
ABMT,3.4  and/or  that PSCT was expected  to result  in  a 
shorter period of  aplasia than ABMT because techniques 
to mobilize large numbers of stem cells into the circulation 
were  performed  during  the  c011ections.’~~~~  This  report 
describes 56 patients with relapsed Hodgkin’s disease (HD) 
and BM abnormalities who were treated with high-dose 
cyclophosphamide, carmustine, and etoposide (CBV) fol- 
lowed by PSCT. 
MATERIALS AND METHODS 
Patient characteristics.  Patients entering this study were candi- 
dates for high-dose chemotherapy because they had HD that had 
relapsed after at least one trial of  chemotherapy, were less than 60 
years of  age, had a Karnofsky performance status of  70 or more, 
and had no major organ impairment unrelated to their HD. 
To receive PSCT rather than ABMT, each patient  must also 
have had some marrow-associated abnormality with no evidence of 
circulating malignant  cells on a blood  smear. Each patient  gave 
written  informed  consent  to  participate  in  the  study  that  was 
approved by the University Institutional Review Board. 
Fifty-six patients, 38 men and 18 women, were treated in this 
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was  37%  and was  as  least  as  good as  that reported for 
relapsed Hodgkin‘s  disease patients treated with CBV and 
ABMT. The 30 patients who had no marrow metastases at 
the  time  of  PSC  harvesting  had  an  actuarial  event-free 
survival of 47%,  while those 26 patients with marrow me- 
tastases  had  a  significantly  different  actuarial  event-free 
survival of 27% (P  = .02). CBV and PSCT for  patients with 
relapsed Hodgkin’s disease who have marrow hypocellular- 
ity in traditional harvest sites or histopathologic evidence of 
BM metastases can result in long-term event-free survival. 
o 1991 by The American Society of Hematology. 
study between February 1986 and March 1990. Their median age 
was 32 years with a range of  17 to 51 years. During their disease 
courses, all but three patients had histopathologically documented 
relapse of HD after achieving a complete response to a chemother- 
apy  trial.  Three  patients  progressed  after  achieving  an  initial 
partial response to a trial of chemotherapy. For this study, MOPP 
alternating with ABVD was considered one chemotherapy trial. If 
a patient relapsed following MOPP, next responded to ABVD, and 
again relapsed, heishe was considered to have failed two trials of 
chemotherapy.  Forty patients had failed less than three trials of 
chemotherapy, and 16 patients had failed three to seven trials. The 
patients were treated with CBV a median of 63 months (range, 9 to 
362 months) after their initial diagnosis of HD. 
At  the  time  of  entry  into  the study,  each  patient  had  some 
BM-associated abnormality. Twenty-six patients  had  histopatho- 
logic evidence of tumor cells in the marrow, 11 patients had tumor 
identified in the BM earlier in their disease course, 17 patients had 
received prior  pelvic irradiation  (three of  them also had  docu- 
mented marrow involvement with tumor earlier  in  their  disease 
course), and  two patients  had  marrow  hypocellularity that pre- 
vented an adequate BM harvest. 
The 26 patients with marrow involvement (marrow-positive) at 
study entry had a median age of 33 years, and the median age of the 
remaining patients (marrow-negative) was 32 years. The median 
number of  chemotherapy trials failed before study entry was two 
for the marrow-negative group and for the marrow-positive group. 
The median  duration  of  the  longest  complete  remission  (CR) 
before  study  entry  was  24.5  months  for  the  marrow-negative 
patients and 18.5 months for the marrow-positive patients. 
Of the 14 patients who had received prior pelvic irradiation as 
the only indication for PSCT, an unsuccessful BM harvest proce- 
dure  had  been  attempted  for  one  patient  at  another  marrow 
transplant center. Six patients were turned down by  other trans- 
plant centers because of biopsy-proven marrow hypocellularity. An 
attempted iliac crest BM biopsy was technically impossible for one 
patient  who had  received  40  Gy  of  pelvic irradiation.  Another 
patient who had received 36 Gy to the pelvis had a positive bone 
scan in the harvest sites. One patient had 0% and 5% cellularity in 
bilateral iliac crest marrow biopsies after 22 Gy of  pelvic irradia- 
tion,  although  he  had  also  received  multiple  prior  courses  of 
chemotherapy. Another patient had an aplastic posterior iliac crest 
biopsy after pelvic irradiation. The remaining three patients had 
received between 30 and 40 Gy of pelvic irradiation. 
The PSC were  col- 
lected  with  4-hour  apheresis  procedures  using  a  Haemonetics 
Model 30 or V50 apheresis device (Haemonetics, Braintree, MA). 
PSC collection and processing  techniques. 
2322  Blood, Vol77, No 11 (June 1). 1991: pp  2322-2325 
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The cells were collected while myelopoiesis was in a steady state, 
ie, neither  chemotherapy nor hematopoietic growth factors were 
used  to mobilize stem cells into the circulation. Thus, an above 
baseline number of  circulating stem cells was not expected.  The 
stem cells were collected on four consecutive apheresis protocol 
studies in the time period covered in this report. The first three 
techniques have been reported by  us previ~usly.~  The most recent 
collections were performed with a modification of the lymphocyte 
collection  protocol  described  in  the  operating  manual  for  the 
Haemonetics Model V50 apheresis device. For each pass, the stem 
cell collection began  after half the platelet band was discharged 
and  ended  when  40  mL  of  the  red  cell  band  was  collected. 
Approximately 10 to 12 passes were performed in 4 hours. At the 
end of the 4-hour procedure, the collected cells were loaded hack 
into the Latham bowl and the apheresis procedure was repeated. 
The collection started when the platelets began to discharge and 
ended when 60 mL of  the red cell band was collected. 
The apheresis procedures were repeated no more often than five 
times weekly. If, at the end of six collection procedures, a total of  at 
least 6.5  x  lo9  mononuclear cellsikg patient weight had not been 
harvested, the procedures were continued until that cell number 
had been reached. Two patients who had peripheral  leukopenia 
less than 3  x  lo9& could not  have a sufficient number of  cells 
collected  and were excluded from  the  study. A median of  nine 
4-hour collection procedures (range, 6 to 21) were performed for 
the 56 patients  who received  a PSCT. The collected  cells were 
cryopreserved with a previously published  method6 that incorpo- 
rated using a 10% concentration of dimethyl sulfoxide (DMSO) as 
a  cryoprotectant  and a  controlled  rate freezer (Cryo-Med,  Mt 
Clemens, MI). The cryopreserved cells were stored in  the vapor 
phase of liquid nitrogen. 
Before hospital- 
ization for the high-dose  therapy but after entry into the study, 
some patients were treated with dexamethasone, 40 mg intrave- 
nously (IV) for 4 consecutive days, cisplatin 100 mpim’ on the first 
day, and cytarabine 4 pim’  IV on the second day (DHAP). This 
therapy was administered  only to patients with bulky disease to 
reduce the tumor burden before high-dose therapy, and to deter- 
mine  if  responsiveness  to  DHAP  would  predict  for  a  better 
outcome  following transplantation.’  Only  23  patients  received 
DHAP because this trial began several months after the PSC study 
began, and because some patients had minimal disease at the time 
of study entry. Thirteen patients received one cycle of DHAP and 
10 patients received two cycles. Before beginning high-dose ther- 
apy, posttransplant radiation therapy to sites of bulky disease was 
planned for three patients. 
Patients then were admitted to the transplant unit of  the hospital 
and CBV was administered. The patients received cyclophospha- 
mide  1.5 g,”’ daily  for  4 consecutive  days (ie,  PSCT  days  -5 
through -2)  carmustine 300 mg/m’  intravenously for 1  day (PSCT 
day -5),  and etoposide 125 mgim’ (16 patients) or 150 mgim’ (40 
patients) administered  twice daily for 3 consecutive days (PSCT 
days -5  through -3).  On day 0, the cryopreserved stem cells were 
removed  from the freezer, transported  to the  patient’s bedside, 
thawed in a 37°C water bath, and immediately infused through a 
central venous catheter without filtration. 
Tumor  response,  patient  survival,  and  eventlfree  survival.  A 
clinical complete response was defined as the disappearance of  all 
evidence of malignant disease as determined by  physical examina- 
tion and imaging studies. For patients who had tumor involvement 
of  the  BM  at  the  time  of  study  entry,  a  complete  response 
designation also required that a posttransplant BM biopsy be free 
of malignant cells. A partial response was defined as a reduction of 
50% or more in tumor volume. A reduction of  less than 50% in 
High-dose therapy and stem cell transplantation. 
tumor volume was considered to represent no response. Survival 
curves were  determined by  the  method  of  Kaplan  and Meier. 
Survival was measured from the day of  PSCT to the day of  death 
from any cause. Event-free survival was measured from the day of 
transplant  to the day of  death from any cause or to the day of 
documented progression of HD. Comparison of  survival curves was 
performed by the log rank method. 
RESULTS 
Tumor response and patient follow-up.  Three patients 
(5%) were not evaluated for tumor response because of  an 
early toxic death 2,  22,  and 25  days after PSCT. Of  the 
remaining 53 patients, 29 patients were judged to have had 
a  complete  clinical  response,  18  patients had  a  partial 
response, and six patients failed to respond. 
As of June 1990, 28 patients were alive with no evidence 
of  disease progression 94 to 1,160 days (median 385 days) 
after PSCT. Eighteen patients were dead. Thirteen patients 
died of progressive HD, three had an early toxic death, one 
patient  committed  suicide  after disease progression  was 
documented, and one patient died of  systemic coccidiomy- 
cosis 230 days after PSCT while in CR with full marrow 
function recovery. 
The actuarial event-free survival for all 56 patients at 39 
months was 37% (Fig 1) and the actuarial overall survival 
was 56% (Fig 2). The projected event-free survival of the 26 
marrow-positive patients was 27% at 3 years, significantly 
less  (P = .02) than  the 3-year projected  47%  event-free 
survival for the 30 marrow-negative  patents (Fig  3). Pa- 
tients whose HD responded  to DHAP before high-dose 
therapy did not have a superior  event-free survival when 
compared with patients whose malignancies were resistant 
to DHAP. 
Two patients died  of  sepsis  or 
hemorrhage 2 and 25 days after PSCT before recovering 0.5 
x  10y/L  circulating  granulocytes.  For  the  remaining  54 
patients, the median time to recover 0.5  x  109/L granulo- 
cytes was 30 days (range, 11 to 68 days) after PSCT. Seven 
Hematologic  recovery. 
I 
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Fig 1.  Actuarial event-free survival for 56 patients with HD. 
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Fig 2.  Actuarial survival for 56 patients with HD. 
patients could not be evaluated for erythrocyte recovery. 
Three of  these  nonevaluable  patients  died  of  sepsis or 
hemorrhage 2, 22, and 25 days after PSCT. The remaining 
four patients experienced documented disease progression 
before becoming independent of  red cell transfusions 30, 
30, 102, and 140 days after PSCT and were then treated 
with marrow toxic therapy. All four patients had marrow 
involvement with  tumor  at the time of  study entry.  The 
remaining  49  patients  became  independent  of  red  cell 
transfusions  (could  maintain  a  hemoglobin  of  approxi- 
mately 9 g/dL)  at a median time of 22 days (range, 7 to 116 
days) following PSCT. The same seven patients who were 
nonevaluable  for  time to erythrocyte  recovery were,  for 
identical  reasons,  also nonevaluable  for time  to platelet 
recovery. Forty-nine patients became independent of plate- 
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Fig 3.  Actuarial event-free survival for patients with HD who did 
(-1  and did not (----I  have BM  metastases at  time of stem cell harvest. 
let transfusions (could maintain a platelet count of approxi- 
mately 20  X  109/L)  at a median of  25 days (range, 8 to 116 
days) after PSCT. 
DISCUSSION 
Twenty-seven  patients with HD and marrow hypocellular- 
ity or lymphomatous involvement of  the marrow who were 
treated with high-dose CBV therapy (or some modification 
thereof)  and  PSCT  have  been  reported  by  five  other 
transplant  center^?.^^"'^ Follow-up reported for 19 of those 
 patient^^,^^'^  showed  that  17 patients were  in  CR  after 
transplant,  one patient  had  a partial  response,  and one 
patient failed to respond. Four patients in CR subsequently 
relapsed  38,  60,  100, and 207 days after transplant,  two 
patients died of  sepsis while in CR 48 and 120 days after 
transplant, and 11 patients remained in  CR 180 to 1,033 
days (median, 249 days) after transplant. 
ABMT  after  CBV  therapy  for HD patients has been 
reported to restore the absolute granulocyte count to 0.5 x 
109/L  at a median of  22 days after transplant."  While the 
patients in this study received their last platelet transfusion 
a median  of  25  days after  PSCT and their  last  red cell 
transfusion  a median of  22 days after PSCT, the median 
time  to  reach  0.5  x  109/L granulocytes  was  30  days. 
Whether  the difference  between  ABMT  and this  study 
indicates a dissimilar ability of  PSC and marrow stem cells 
to  restore  granulocytopoiesis  or  is  a  reflection  of  the 
marrow abnormality each PSCT patient  had is uncertain. 
No  group  of  patients  with  marrow  abnormalities  who 
received ABMT is  available for comparison  of  speed  of 
marrow function recovery following CBV. The incidence of 
early death following CBV and ABMT for HD has been 
reported to be 8.6%.'*  The incidence of  early death follow- 
ing CBV and PSCT in this study was 5.4%, suggesting the 
longer time  to recover  0.5  x  109/L granulocytes did not 
impact on procedure-related mortality. 
Because  patients  with  histopathologically  identifiable 
HD in BM are not routinely treated with high-dose therapy 
and ABMT, the outcome of  the 26  patients with marrow 
metastases  in  this  study  is  of  particular  interest.  This 
subgroup of  patients demonstrated an actuarial event-free 
survival of  27%  3 years  after  PSCT.  A  large  series  of 
patients  who  received  ABMT  after  the same high-dose 
chemotherapy had an actuarial event-free survival of  38% 
at 3 years." Follow-up of the 30 marrow-negative patients in 
the present  study  showed  a  3-year  actuarial  event-free 
survival of 48%, a statistically significant  difference (P  = .02, 
log rank) from the 26 patients who had marrow metastases. 
Accurate  interpretation  of  this  difference  will  require a 
randomized prospective study that is currently underway. 
Autologous PSCT can be considered  for patients with 
relapsed HD who are candidates for high-dose therapy but 
have marrow hypocellularity in traditional marrow harvest 
sites or histopathologic evidence of  BM metastases and are 
not eligible for ABMT. Longer patient follow-up is needed 
to determine  if  cure can result, but long-term  event-free 
survival has been observed. 
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From PERIPHERAL STEM CELL TRANSPLANTS  2325 
REFERENCES 
1. Juttner CA, To LB, Ho JQK, Bardy PG, Dyson PG, Haylock 
DN,  Kimber  RJ:  Early  lympho-hemopoietic  recovery  after au- 
tografting  using  peripheral  blood  stem  cells  in  acute  non- 
lymphoblastic leukemia. Transplant Proc 20:40,1988 
2.  Fermand JP, Levy  Y, Gerota J, Benbunan  M,  Cosset JM, 
Castaigne S, Seligmann M, Brouet  JC: Treatment of  aggressive 
multiple  myeloma  by  high-dose  chemotherapy  and  total  body 
irradiation  followed by blood  stem cells autologous graft. Blood 
73:20,1989 
3.  Williams  SF, Bitran  JD, Richards  JM, DeChristopher  PJ, 
Barker E, Conant J, Golomb HM, Orlina AR: Peripheral blood- 
derived stem cell collections for use in autologous transplantation 
after high  dose  chemotherapy:  An  alternative  approach.  Bone 
Marrow Transplant 5:129, 1990 
4.  Korbling M, Holle R, Haas R, Knouf W, Dorken B, Ho AD, 
Kuse R, Pralle H, Fliedner TM, Hunstein W  Autologous blood 
stem-cell  transplantation  in  patients  with  advanced  Hodgkin’s 
disease and prior radiation to the pelvic site. J Clin Oncol 8:978, 
1990 
5.  Kessinger A, Armitage JO, Smith DM, Landmark JD, Bier- 
man  PJ,  Weisenburger  DD. High-dose therapy  and autologous 
peripheral  blood stem cell transplantation  for patients with lym- 
phoma. Blood 74:1260,1989 
6.  Kessinger A, Armitage JO, Landmark JD,  Smith DM, Weisen- 
burger DD: Autologous peripheral hematopoietic stem cell trans- 
plantation restores hematopoietic function following marrow abla- 
tive therapy. Blood 71:723,1988 
7.  Bierman PJ, Vose JM, Armitage JO: Chemotherapy sensitiv- 
ity predicts a better outcome with high-dose therapy and autotrans- 
plantation in Hodgkin disease. Proc Am SOC  Clin Oncol9:259,1990 
8.  Lasky LC, Hurd DD, Smith JA, Haake R  Peripheral blood 
stem cell collection and use in Hodgkin’s disease. Comparison with 
marrow in autologous transplantation. Transfusion 29:323, 1989 
9.  Reiffers J, Leverger G, Marit S, Castaigne S, Tilly H, Lepage 
E, Henon P, Douay L, Troussard X: Haematopoietic  reconstitu- 
tion after autologous blood stem cell transplantation,  in Gale RP, 
Champlin RE (eds): Bone Marrow Transplantation  Current Con- 
troversies. UCLA Symposia on Molecular and Cellular Biology, 
New Series Volume 91. New York, NY, Liss, 1989, p 313 
10. Zander AR, Lyding J, Cockerill KJ, Aksamit I, Shepherd R: 
Autologous blood stem cell transplantation,  in Dicke KA, Spitzer 
G,  Jagannath  S,  Evinger-Hodges  MJ  (eds):  Autologous  Bone 
Marrow Transplantation, Proceedings of  the Fourth International 
Symposium. Houston,  TX,  University  of  Texas  MD Anderson 
Cancer Center, 1989, p 713 
11. Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez 
WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ,  Hagemeister 
FB, McLaughlin P, Cabanillas F, Spitzer G: Prognostic factors for 
response and survival after high-dose cyclophosphamide, carmus- 
tine and etoposide with autologous bone marrow transplantation 
for relapsed Hodgkin’s disease. J Clin Oncol7:179,1989 
12. Jagannath S, Annitage JO, Dicke KA, Tucker SL, Velasquez 
WS, Smith K, Vaughan WP, Kessmger A, Horwitz LJ, Hagemeister 
FB,  Cabanillas  F,  Spitzer  G:  Timing  of  high  dose  CBV  and 
autologous bone marrow  transplantation  in  the  management  of 
relapsed or refractory Hodgkin’s disease, in Dicke KA, Spitzer G, 
Jagannath S, Evinger-Hodges MJ (eds): Autologous Bone Marrow 
Transplantation, Proceedings of  the Fourth International Sympo- 
sium.  Houston  TX, University of  Texas MD Anderson  Cancer 
Center, 1989, p 275 
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From 